Management of Anosmia in COVID-19: A Comprehensive Review
- PMID: 36407192
- PMCID: PMC9670825
- DOI: 10.7759/cureus.30425
Management of Anosmia in COVID-19: A Comprehensive Review
Abstract
With the evolving understanding of COVID-19, a thorough analysis of the effects of this unique coronavirus on the affected people's olfactory abilities could highlight the disease's specific course of treatment. Researchers have discovered that the neurological side effects of SARS-CoV-2 infection include acute anosmia and ageusia. This work aims to review the relevant mechanisms, provide information on COVID-19-related anosmia, and suggest a novel approach to treating long-term anosmia brought on by coronavirus disease. For that, we did a thorough literature assessment of the subject from various online resources, including PubMed, Scopus, and Google Scholar. We evaluated the publications that described anosmia in COVID-19 and its management. In patients with SARS-CoV-2 infections, the angiotensin-converting enzyme two receptor plays a crucial role in the anosmia process. Olfactory systems are directly harmed by new coronaviruses when they connect with sustentacular cells' ACE-2 (Angiotensin converting enzyme-2) receptors. Other suggested processes include the virus's infiltration of the olfactory nerve and the ensuing local inflammation. Therefore, neuroprotective, anti-inflammatory, or depolarizing medications may be helpful for COVID-19 individuals who have lost their sense of smell. According to the available data, we found out olfactory training, topical or oral corticosteroids, caffeine, insulin, or minocycline may effectively treat COVID-19 odor loss. A novel method of treating long-term COVID-19 with persistent anosmia can be suggested based on recent investigations. The path to effective anosmia management is still somewhat hazy, but there is hope that we can find the right treatment plan with the right clinical trials and additional research. People who lost their sense of smell during COVID-19 can be reassured that recovery is typically possible.
Keywords: anosmia; coronavirus; covid-19; loss of smell; management; olfactory dysfunction; treatment.
Copyright © 2022, Khurana et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review.Eur J Pharmacol. 2021 Dec 5;912:174582. doi: 10.1016/j.ejphar.2021.174582. Epub 2021 Oct 19. Eur J Pharmacol. 2021. PMID: 34678243 Free PMC article. Review.
-
Mechanism of Anosmia Caused by Symptoms of COVID-19 and Emerging Treatments.ACS Chem Neurosci. 2021 Oct 20;12(20):3795-3805. doi: 10.1021/acschemneuro.1c00477. Epub 2021 Oct 5. ACS Chem Neurosci. 2021. PMID: 34609841 Review.
-
Negative correlation between ACE2 gene expression levels and loss of taste in a cohort of COVID-19 hospitalized patients: New clues to long-term cognitive disorders.Front Cell Infect Microbiol. 2022 Sep 29;12:905757. doi: 10.3389/fcimb.2022.905757. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36250059 Free PMC article.
-
Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell.Eur Arch Otorhinolaryngol. 2021 Aug;278(8):3113-3117. doi: 10.1007/s00405-020-06520-8. Epub 2021 Jan 9. Eur Arch Otorhinolaryngol. 2021. PMID: 33423106 Free PMC article.
-
Olfactory training for olfactory dysfunction in COVID-19: A promising mitigation amidst looming neurocognitive sequelae of the pandemic.Clin Exp Pharmacol Physiol. 2022 Apr;49(4):462-473. doi: 10.1111/1440-1681.13626. Epub 2022 Feb 10. Clin Exp Pharmacol Physiol. 2022. PMID: 35090056 Review.
Cited by
-
Diode laser in management of loss of taste sensation in patients with post-COVID syndrome: a randomized clinical trial.BMC Oral Health. 2023 May 6;23(1):263. doi: 10.1186/s12903-023-02952-w. BMC Oral Health. 2023. PMID: 37149582 Free PMC article. Clinical Trial.
-
Design and Evaluation of a Potential Non-Invasive Neurostimulation Strategy for Treating Persistent Anosmia in Post-COVID-19 Patients.Sensors (Basel). 2023 Jun 25;23(13):5880. doi: 10.3390/s23135880. Sensors (Basel). 2023. PMID: 37447728 Free PMC article.
-
SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids.Front Microbiol. 2023 Nov 23;14:1320856. doi: 10.3389/fmicb.2023.1320856. eCollection 2023. Front Microbiol. 2023. PMID: 38075874 Free PMC article.
-
Distinguishing COVID-19 from seasonal influenza in patients under age 65 years-a retrospective observational cohort study comparing the 2009 influenza A (H1N1) and 2022 SARS-CoV-2 pandemics.Front Cell Infect Microbiol. 2023 Jul 18;13:1179552. doi: 10.3389/fcimb.2023.1179552. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37533930 Free PMC article.
-
Clinical presentations, systemic inflammation response and ANDC scores in hospitalized patients with COVID-19.Sci Rep. 2024 Sep 28;14(1):22480. doi: 10.1038/s41598-024-73001-x. Sci Rep. 2024. PMID: 39341876 Free PMC article.
References
-
- Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. Mao L, Wang M, Chen S, et al. MedRxiv. 2020
-
- The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: A systematic review and meta-analysis. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. Otolaryngol Head Neck Surg. 2020;163:3–11. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous